Page last updated: 2024-12-07

bradykinin, des-arg(9)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Des-Arg9-bradykinin (DABK) is a peptide formed by the enzymatic removal of the C-terminal arginine residue from bradykinin, a potent vasoactive peptide. DABK is a potent agonist of the bradykinin B1 receptor, which is upregulated in inflammatory conditions. It has been shown to have a variety of biological effects, including vasodilation, pain, inflammation, and tissue repair. DABK has been studied as a potential therapeutic agent for the treatment of inflammatory conditions, such as arthritis and asthma. It has also been investigated for its potential to promote wound healing.'

bradykinin, des-Arg(9)-: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID105044
CHEMBL ID1890370
CHEBI ID133068
MeSH IDM0083048

Synonyms (37)

Synonym
bradykinin[1-8]
NCGC00167250-01
des-arg(9)-bradykinin
9-des-arg-bk
bradykinin, des-arginine(9)-
bradykinin, des-arg(9)-
9-de-l-argininebradykinin
9-de-arg-bradykinin
15958-92-6
l-arg-l-pro-l-pro-gly-l-phe-l-ser-l-pro-l-phe
1-8-bradykinin
rppgfspf
CHEBI:133068
l-arginyl-l-prolyl-l-prolylglycyl-l-phenylalanyl-l-seryl-l-prolyl-l-phenylalanine
arg-pro-pro-gly-phe-ser-pro-phe
[des-arg9]-bradykinin
(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-1-[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpr
CHEMBL1890370
bradykinin, des-arg(1)-
bradykinin, de-arginine(1)-
des-arg(1) bradykinin
bradykinin, 1-de-l-arginine-
1-des-arg-bradykinin
58qe2vve3q ,
unii-58qe2vve3q
bradykinin (1-8)
AKOS024457375
mfcd00236892
(des-arg9)-bradykinin
bradykinin(1-8)
(des-arg9)-bradykinin acetate (h-l-arg-l-pro-l-pro-gly-l-phe-l-ser-l-pro-l-phe-oh)
HY-P0298
(s)-2-((s)-1-((s)-2-((s)-2-(2-((s)-1-((s)-1-((s)-2-amino-5-guanidinopentanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)-3-phenylpropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanoic acid
dabk
des-arg9 bradykinin
desarg9-bk
alanine, n-(1-(n-(n-(n-(1-(1-l-arginyl-l-prolyl)-l-prolyl)glycyl)-3-phenyl-l-alanyl)-l-seryl)-l-prolyl)-3-phenyl-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These drugs have a variety of acute adverse effects, the nature of which depends on the clinical context, and which include angioedema, anaphylactoid reactions in hemodialysis patients, and severe hypotensive reactions during blood product transfusions."( [Physiopathology of the acute adverse effects of angiotensin-converting-enzyme inhibitors].
Adam, A; Désormeaux, A; Moreau, ME, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" ELN441958 is a novel small molecule bradykinin B(1) receptor antagonist exhibiting high oral bioavailability and potent systemic efficacy in rhesus monkey inflammatory pain."( Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
Bova, MP; Butelman, ER; Chavez, RA; Chen, L; Dreyer, M; Fukuda, JY; Garofalo, AW; Hawkinson, JE; Holcomb, R; Hom, DS; Ko, MC; Liao, A; Malmberg, AB; Ruslim, L; Samant, B; Simmonds, S; Szoke, BG; Wadsworth, A; Zeitz, KP; Zhang, H; Zmolek, W, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" Des-Arg9-bradykinin-mediated relaxation was inhibited by the specific B1 receptor antagonist [Leu8]des-Arg9-bradykinin which produced parallel shifts in the dose-response curve."( Relaxation of isolated mesenteric arteries by des-Arg9-bradykinin stimulation of B1 receptors.
Churchill, L; Ward, PE, 1986
)
0.27
" The dose-response for bradykinin-stimulated prostaglandin synthesis was similar in Swiss 3T3 cells and CPAE cells."( Distinct bradykinin receptors mediate stimulation of prostaglandin synthesis by endothelial cells and fibroblasts.
Axelrod, J; Burch, RM; Conklin, BR; Steranka, LR, 1988
)
0.27
" Des-Arg9-bradykinin-mediated contractions were inhibited by the specific bradykinin B1 receptor antagonist des-Arg9-[Leu8]bradykinin which produced parallel shifts in the dose-response curve to the selective bradykinin B1 receptor agonist."( Bradykinin B1 receptors in human umbilical vein.
Antúnez, P; Pérez, H; Rothlin, RP; Sardi, SP, 1997
)
0.3
" However, when animals were pre-treated with BCG, the dose-response curves for both B1 agonists were shifted 2 to 8-fold to the left."( Systemic treatment with Mycobacterium bovis bacillus Calmette-Guérin (BCG) potentiates kinin B1 receptor agonist-induced nociception and oedema formation in the formalin test in mice.
Calixto, JB; de Campos, RO; Henriques, MG, 1998
)
0.3
"To study whether a sepsis-induced increase in des-Arg9-bradykinin (des-Arg9-BK) and bradykinin (BK) B1-receptor activity participates in the observed increase in pulmonary vascular resistance in neonatal group B streptococcal sepsis (GBS), isometric force bioassays of pulmonary artery (PA) rings were studied, after 4-h exposure to either Krebs or GBS, by using the following protocols: 1) BK dose-response curve, 2) vascular response to BK with NG-nitro-L-arginine methyl ester (L-NAME), and 3) response to des-Arg9-BK (BK metabolite and B1 agonist)."( Influence of group B streptococci on piglet pulmonary artery response to bradykinin.
Goldberg, RN; Herbert, D; Laskey, R; Van Breemen, C; Whitehurst, RM, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bradykinin receptor B2 agonistA bradykinin agonist that binds to and activates bradykinin B2 receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
oligopeptideA peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
RAS and bradykinin pathways in COVID-19113
Kinin-Kallikrein pathway31

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase kappa isoform 1Homo sapiens (human)Potency15.00300.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID167556In vitro 50 % Maximal response in rabbit aorta expressing B1 receptor1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Biological activities of photoaffinity labeling analogues of kinins and their irreversible effects on kinin receptors.
AID165431The compound was tested in vitro on rabbit aorta for residual response in presence of ultraviolet light1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Biological activities of photoaffinity labeling analogues of kinins and their irreversible effects on kinin receptors.
AID167554In vitro 50 % Maximal response in rabbit aorta expressing B1 receptor1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Biological activities of photoaffinity labeling analogues of kinins and their irreversible effects on kinin receptors.
AID165499Intrinsic activity was determined1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Biological activities of photoaffinity labeling analogues of kinins and their irreversible effects on kinin receptors.
AID167555Percent agonistic activity in rabbit aorta expressing B1 receptor relative to bradykinin1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Biological activities of photoaffinity labeling analogues of kinins and their irreversible effects on kinin receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (295)

TimeframeStudies, This Drug (%)All Drugs %
pre-199046 (15.59)18.7374
1990's143 (48.47)18.2507
2000's84 (28.47)29.6817
2010's17 (5.76)24.3611
2020's5 (1.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.44 (24.57)
Research Supply Index5.73 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (39.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (2.33%)5.53%
Reviews6 (2.00%)6.00%
Case Studies3 (1.00%)4.05%
Observational0 (0.00%)0.25%
Other284 (94.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]